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Summary
 
Injections of soluble proteins are poorly immunogenic, and often elicit antigen-specific toler-
ance. The mechanism of this phenomenon has been an enduring puzzle, but it has been specu-
lated that tolerance induction may be due to antigen presentation by poorly stimulatory, resting
B cells, which lack specific immunoglobulin receptors for the protein. In contrast, adjuvants, or
infectious agents, which cause the release of proinflammatory cytokines such as tumor necrosis
factor 
 
a
 
 and interleukin 1
 
b
 
 in vivo are believed to recruit and activate professional antigen-
presenting cells to the site(s) of infection, thereby eliciting immunity. Here we show that ad-
ministration of Flt3 ligand (FL), a cytokine capable of inducing large numbers of dendritic cells
(DCs) in vivo, (
 
a
 
) dramatically enhances the sensitivity of antigen-specific B and T cell re-
sponses to systemic injection of a soluble protein, through a CD40–CD40 ligand–dependent
mechanism; (
 
b
 
) influences the class of antibody produced; and (
 
c
 
) enables productive immune
responses to otherwise tolerogenic protocols. These data support the hypothesis that the deli-
cate balance between immunity and tolerance in vivo is pivotally controlled by DCs, and un-
derscore the potential of FL as a vaccine adjuvant for immunotherapy in infectious disease and
other clinical settings.
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A
 
productive immune response against an invading
pathogen occurs through the clonal expansion of
functionally competent B and T lymphocytes that specifi-
cally recognize the pathogen through surface receptors for
antigen (1). It is well established that soluble proteins do
not induce productive immunity unless they enter the
body with adjuvants or infectious agents (2–6). Expansion
of antigen-specific T cells after exposure to soluble antigen
is only transient and is followed by their subsequent dele-
tion and/or functional unresponsiveness, a state that has
been termed “clonal anergy” (7–10). It has been proposed
that soluble protein antigens are presented to T cells by
resting B cells, which lack critical costimulatory molecules
on their surface and thus often induce immunological tol-
erance (11–14). Adjuvants or infectious organisms are
thought to act by recruiting professional APCs to the site(s)
of infection, and by directly stimulating these APCs to ex-
press costimulatory molecules (9, 15–17). The expression
of costimulatory molecules, such as CD80 and CD86, on
these cells bestows them with immunostimulatory capaci-
ties, and they are thus able to present antigen to T cells in
an immunogenic fashion.
One cell type that is thought to play a crucial role in the
initiation of immunity is the dendritic cell (DC)
 
1
 
 (18, 19).
By in situ staining, DCs located in the T cell zones of
spleens and lymph nodes have been shown to express high
levels of CD86 (20), compared with B cells and other
APCs. Indeed, DCs by virtue of their excellent antigen
capture, processing, and presentation capacities, and their
mobility throughout the body, have been hailed as “na-
ture’s adjuvants” (18). Research into DCs and the roles
they play in the regulation of immune responses has been
somewhat hampered by their rarity in tissues. One recent
solution to this problem has been the identification of DC
growth factors such as Flt3 ligand (FL), which has been
shown to induce a profound expansion of mature DC sub-
sets in various tissues in mice (21, 22). Such DCs constitu-
tively express MHC class II antigens, CD86, and CD40,
and are as efficient as DCs from untreated mice in priming
antigen-specific T cells in vitro and in vivo. Here we inves-
 
1
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tigate the effect of FL on B and T cell responses to systemic
injection of soluble proteins. We show that FL administra-
tion dramatically enhances antigen-specific antibody re-
sponses as well as T cell proliferation, through a mechanism
involving CD40–CD40 ligand (CD40L) interaction. Fur-
thermore, this treatment appears to prevent the establish-
ment of peripheral T cell tolerance, which is induced by
systemic injection of soluble antigens.
 
Materials and Methods
 
Mice.
 
DO11.10 TCR mice (23) were bred in a pathogen-
free facility according to the National Institutes of Health guide-
lines. BALB/c and C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and kept in a specific
pathogen-free facility. For adoptive transfers, age- and sex-
matched BALB/c recipients were given 2.5 
 
3 
 
10
 
6
 
 DO11.10
TCR transgenic T cells intravenously as described previously (8).
 
Injections.
 
Mice (2–10/group) were injected once daily (sub-
cutaneously at the nape of the neck) with 1 
 
m
 
g mouse serum
albumin (MSA) plus 10 
 
m
 
g of recombinant human FL (hu-
man Chinese hamster ovary cell–derived) for 9 consecutive d.
Chicken OVA (Sigma Chemical Co., St. Louis, MO) was freshly
prepared in PBS, filtered through a 0.45-
 
m
 
m pore size filter, and
deaggregated by centrifugation at 15,000 
 
g
 
 for 10 min. Footpad
injections were given in a volume of 25 
 
m
 
l. In the tolerance ex-
periments, intraperitoneal injections were given in a volume of
200 
 
m
 
l. OVA was emulsified in CFA (Sigma Chemical Co.), as
described previously (8). The M158 antibody against murine
CD40L was prepared at Immunex (Seattle, WA), and found to be
endotoxin-free. This was injected in a volume of 25 
 
m
 
l in the
footpad. A rat IgG antibody (M132) made at Immunex was used
as an isotype control.
 
Flow Cytometry.
 
Cell suspensions were prepared from the
popliteal draining lymph nodes and incubated on ice with PE-
labeled anti-CD4 (PharMingen, San Diego, CA) and FITC-labeled
KJ1-26 mAb (24), as previously described (8). A FACScan
 
Ò
 
 flow
cytometer (Becton Dickinson, San Jose, CA) was used to collect
and analyze 20,000 events that had the light scatter properties of
lymphocytes.
 
In Vitro Cultures.
 
Various times after priming with OVA in
the hind footpads, 5 
 
3 
 
10
 
5
 
 popliteal lymph node cells were plated
in triplicate in 96-well flat-bottomed plates (Costar, Cambridge,
MA) in 200 
 
m
 
l of DMEM complete supplemented with 5% FBS,
together with different concentrations of OVA 323–339 peptide.
Proliferative responses were assessed after 72 h of culture in a hu-
midified atmosphere of 5% CO
 
2
 
 in air. Cultures with pulsed with
0.5 
 
m
 
Ci [
 
3
 
H]thymidine for 5 h and the cells were harvested onto
glass fiber sheets for counting on a gas-phase 
 
b
 
 counter. For cy-
tokine assays, aliquots of culture supernatants were removed after
72 h, pooled, and assayed for the presence of IFN-
 
g
 
, IL-2, IL-4,
and IL-10 by ELISA.
 
Measurement of OVA-specific Serum Titers.
 
96-well ELISA plates
(Maxisorp; Nunc, Naperville, IL) were coated overnight with
1 
 
m
 
g/well OVA in PBS at 4
 
8
 
C, blocked with PBS/5% FBS, and
washed with PBS/0.1% Tween 20. Serum samples were diluted
in PBS/5%FBS (starting at 1:100), and threefold dilutions were
made. Plates were incubated for 2 h at room temperature,
washed, and incubated with alkaline phosphatase-conjugated
anti-IgG1 (1:2,000; PharMingen), anti-IgG2a, anti-IgG2b or
anti-IgM (1:1,000; PharMingen) detecting antibodies for an addi-
tional 2 h at room temperature. Plates were washed again, and
enzyme activity was detected with 
 
p
 
-nitrophenyl phosphate diso-
dium (Sigma Chemical Co.). The amount of reaction product
was assessed on an ELISA plate reader at an OD of 405 nm using
the Deltasoft program (DeltaPoint, Monterey, CA). Multiple
point analysis was performed on each set of isotype titrations using
the BIOASSAY program (Immunex, Seattle, WA), selecting a
maximum value for each isotype and determining for each sample
the dilution giving half-maximal OD value, thus generating arbi-
trary unit per milliliter values as previously described (24a).
 
Cytokine ELISAs.
 
IFN-
 
g
 
, IL-2, IL-10, and IL-4 were quan-
tified by ELISAs adapted from PharMingen protocols. In brief,
Nunc ELISA plates (Maxisorp; Nunc) were coated with 100 
 
m
 
l
of the following antibodies diluted in 0.1 M NaHCO
 
3
 
 for 6 h:
R46A2 (mIFN-
 
g
 
 at 1 
 
m
 
g/ml); 11B11 (mIL-4 at 1 
 
m
 
g/ml); and
purified anti-mIL-2 and anti-mIL-10 (PharMingen) at 2 
 
m
 
g/ml.
The plates were then washed in PBS/0.1% Tween 20 and
blocked with PBS/5% FBS for 6 h. Serial dilutions (twofold) of
the samples were made in PBS/5% FBS and added to the plate
overnight at 4
 
8
 
C. Twofold, serial dilutions of the standards
(PharMingen) were made at the following starting concentra-
tions: mIFN-
 
g
 
 (18 ng/ml); mIL-4 (500 pg/ml); mIL-10 (10 ng/
ml); mIL2 (10-ng/ml). After overnight incubation, the plates
were washed, and biotinylated anti-cytokine antibodies (Phar-
Mingen) were added at the following dilutions: mIFN-
 
g
 
 at 0.5
 
m
 
g/ml; mIL-4 at 0.25 
 
m
 
g/ml; mIL-10 at 10 ng/ml; mIL-2 at 10
ng/ml. 2 h later the plates were washed and incubated with
streptavidin-horseradish peroxidase (Zymed, San Francisco, CA)
diluted in PBS/Tween 20 at 1:2,000. 2 h later, the plates were
washed and the bound peroxidase was detected with TMB Micro-
well substrate (Kirkegaard & Perry Labs., Gaithersburg, MD).
The amount of reaction product was assessed on an ELISA plate
reader at an OD of 450 nm. The detection limits were: 100 pg/ml
for IFN-
 
g
 
, 100 pg/ml for IL-2, and 20 pg/ml for IL-10.
 
Results and Discussion
 
FL Administration Dramatically Enhances Antibody Responses
against Soluble Proteins.
 
We examined whether FL-treated
mice had enhanced potential to mount antigen-specific
immune responses against soluble antigens. C57BL/6 or
BALB/C mice were treated with either FL or MSA (con-
trol) for 9 d. This FL treatment regimen results in up to a
30-fold expansion of DCs in spleen and various other tis-
sues (21, 22). These animals were then injected subcutane-
ously with various doses of soluble OVA or OVA in the
adjuvant RIBI (OVA/RIBI) on the final day of FL treat-
ment. 3 wk later, the mice were boosted with a second in-
jection of OVA or OVA/RIBI and the serum anti-OVA
antibody titers were measured 7 d later. FL treatment dra-
matically enhanced IgG2a anti-OVA antibody titers in
both C57BL/6 and BALB/C mice, compared with MSA-
treated controls (Fig. 1, 
 
A
 
 and 
 
B
 
). The titers of IgG2a
OVA-specific antibody in FL-treated mice were, in some
cases, increased up to 10,000-fold, and were as high as
those in mice immunized with OVA/RIBI. In the BALB/C
strain, in two experiments, a minor subset of the MSA-
treated mice showed a significant IgG2a response when in-
jected with 300 
 
m
 
g of soluble OVA (Fig. 1 
 
B
 
). A lower
(but detectable) level can also be seen in a single C57BL/6
mouse, in response to 100 
 
m
 
g of OVA. In both strains, the 
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minor subsets of responders gave titers above the threshold
of detectability in this assay (
 
,
 
5 U/ml). The reason(s) for
this aberrant response is at present unclear, but may simply
reflect variability between mice.
IgG1 anti-OVA antibody titers in both strains of FL-
treated mice were elevated 3–10-fold over control mice at
the 1,000-
 
m
 
g dose of antigen (
 
P
 
 
 
, 
 
0.01). However, little
to no enhancement of IgG1 was observed at lower antigen
doses, with the exception of a subset of responders at the
lowest antigen dose in FL-treated C57BL/6 mice. The
IgM titers also showed increases at the higher doses. There
were also marked increases in the IgG2b anti-OVA titers in
FL-treated BALB/C mice, but more modest increases in
the C57BL/6 strain. The IgE and IgG3 titers were unaf-
fected by FL treatment (data not shown). Titers of total Ig
(IgM, IgG1, IgG2a, IgG2b, IgG3, and IgE) were unaf-
fected by FL treatment, suggesting that the effect of FL oc-
curred in an antigen-specific way (data not shown), with a
preferential skewing towards an IgG2a response.
 
FL Injection Enhances the Clonal Expansion and Proliferative
Capacity of Antigen-specific T Cells In Vivo and In Vitro.
 
To investigate the effect of FL treatment on antigen-spe-
cific T cell responses, we used TCR transgenic mice that
contain rearranged TCR-
 
a
 
 and TCR-
 
b
 
 genes encoding a
TCR specific for OVA 323–339 bound to I-A
 
d
 
 class II
MHC molecules (DO11.10 mice; reference 23). TCR
transgenic T cells were adoptively transferred into synge-
neic BALB/C recipients, such that they constituted a small
but detectable proportion of all T cells (8, 9). In this sys-
tem, the fate of the OVA-specific, transgenic T cells could
Figure 1. Antigen-specific, sec-
ondary serum antibody titers in
FL-treated (gray bars) versus
MSA-treated (control; white bars)
C57BL/6 (A) and BALB/c (B)
mice after subcutaneous OVA
challenge. Data are derived from
five independent experiments.
Each dot represents a single
mouse and histograms represent
the arithmetic means. 
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be followed with the KJ126 clonotypic antibody (24). The
reconstituted mice were injected with 10 mmol OVA in
the footpad, in either the presence or absence of FL treat-
ment (Fig. 2 
 
A
 
). The CD4
 
1
 
, OVA-specific T cell response
in the draining lymph node was monitored by flow cytom-
etry. Injection of OVA elicited a significant clonal expan-
sion of the KJ126
 
1
 
CD4
 
1
 
 cells in the draining lymph nodes,
consistent with previous reports (9). FL treatment signifi-
cantly enhanced the percentage of KJ126
 
1
 
CD4
 
1
 
 cells in
vivo, 7 d after challenge (2.1% soluble OVA versus 5.9%
soluble OVA 
 
1
 
 FL; Fig. 2, 
 
B
 
 and 
 
C
 
). There was a corre-
sponding increase in the absolute numbers of KJ126
 
1
 
CD4
 
1
 
cells at day 7 (Fig. 2 
 
D
 
). Thus, FL treatment enhanced the
clonal expansion of antigen-specific T cells induced by ad-
ministration of a soluble protein antigen. This two- to
threefold increase in the frequency and the absolute num-
bers of such cells is similar to the enhancement observed
with a natural adjuvant such as LPS in this adoptive transfer
system (9, 25). Interestingly, this increase is apparent only
at day 7, when the response is on the decline. Therefore, it
is conceivable that FL is somehow retarding the elimina-
tion of cells rather than, or in addition to, enhancing their
expansion.
FL treatment alone, in the absence of OVA injection,
failed to elicit any response above the basal levels. The ab-
solute number and activation state (assessed by CD69,
CD44, CD45Rb, and CD62L expression), of the non-
antigen-specific (KJ126
 
2
 
CD4
 
1
 
) T cells were unaffected by
FL treatment (data not shown), suggesting that FL treatment
enhances T cell responses in an antigen-specific manner.
Previous work in this system has shown that productive
T cell immunity is elicited only when the antigen is in-
jected with an adjuvant, and that injections of soluble anti-
gens only result in a transient and abortive clonal expan-
sion, in which the antigen-specific T cells cannot be
efficiently restimulated in vitro with peptide (8, 9, 25).
Therefore, we examined the in vitro proliferative capacity
of the OVA-specific T cells from the mice injected with
OVA (with or without FL) by culturing single-cell suspen-
sions of the draining lymph nodes from the various cohorts
of mice, in the presence of varying concentrations of OVA
323–339 peptide. As shown in Fig. 3 
 
A
 
, mice that received
Figure 2. Effect of FL on antigen-specific T cell responses. (A) Experimental design. Mice were treated for 10 d (from day 29 to 0) with FL or MSA,
and 10 mmol (423 mg) of OVA was injected in the footpads on day 0. The draining popliteal lymph nodes were removed for phenotypic and functional
analysis at days 2, 4 and 7. (B) Flow cytometry profiles (CD4 versus KJ126) from day 5 of the response from a representative experiment. (C and D) The
kinetics of expansion of antigen-specific T cells in vivo. At day 7 there is a significant enhancement in frequency (C) and absolute numbers (D) of antigen-
specific T cells in FL-treated mice (P , 0.01). h, recon; e, OVA; s, OVA 1 FL; n, FL; quartered square, OVA/CFA. Data are representative of 10 experi-
ments. 
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an injection of OVA without FL treatment had greatly di-
minished responses compared with those that received FL
treatment, or those challenged with OVA/CFA, at each of
the time points examined. As observed previously, injec-
tion of soluble OVA renders the mice unresponsive to an
in vitro challenge with OVA 323–339 (8). However, FL
treatment prevented this unresponsiveness (Fig. 3 A). Fur-
thermore, FL treatment alone (in the absence of OVA) did
not increase the proliferative capacity of T cells above the
background controls. This suggests that the observed adju-
vant effects of FL are indeed antigen-specific, and not
caused by some generic effect of FL on all T cells. It should
be noted that the concentration of OVA 323–339 peptide
required to elicit a half maximal response diminished with
time. Thus, at day 2, half maximal response was achieved
with 0.01 mM of peptide, whereas at day 6 only 0.0001
mM peptide was required (Fig. 3 A). This may reflect a
state of transient refractoriness in the T cells after antigen-
mediated stimulation in vivo.
Consistent with their increased proliferative capacity,
OVA-specific T cells from mice injected with OVA plus
FL made significantly higher levels of IL-2, IFN-g, and IL-
10, when re-stimulated in vitro (Fig. 3 B). IL-4 was not de-
tectable. The enhanced IFN-g production is consistent
with the dramatic increase in OVA-specific IgG2a titers
observed (Fig. 1), and is likely to be mediated by IL-12
produced by the DCs in vivo (22, 26, 27).
A Role for CD40–CD40L Interaction in the Immune-
enhancement Effects of FL. There is strong evidence that
CD40–CD40L interaction is crucial for humoral and cellu-
lar immune responses (28, 29). We examined the potential
role CD40–CD40L interaction could play in mediating the
enhanced immune responses, since DCs from FL-treated
mice express significant levels of CD40 (21, 22). FL- or
Figure 3. (A) In vitro restimulation of antigen-specific T cells expanded in vivo (by injecting 10 mmol OVA in the footpad, as described in the legend to
Fig. 2) with varying concentrations of OVA 323–339 peptide. h, recon; e, OVA; s, OVA 1 FL; n, FL alone; quartered square, OVA/CFA. (B) Cytokine
production by antigen-specific T cells restimulated in vitro with varying concentrations of OVA 323–339 peptide. In vitro cultures were set up 6 d after
priming in vivo. Culture supernatants were harvested 72 h later and assayed for cytokines by ELISA. The detection limits were 100 pg/ml for IFN-g and IL-2
and 20 pg/ml for IL-10. h, OVA; e, OVA 1 FL; s, OVA/CFA. Data are representative of 10 (A) and 3 (B) independent experiments.2080 Flt3 Ligand as an Adjuvant
MSA-treated mice were injected in the footpad with OVA
(Fig. 2 A), and on days 21, 0, 11, and 12 200 mg of the
M158 antibody (antagonistic against murine CD40L) was
injected intraperitoneally. Antigen-specific T cell responses
were measured on day 5. As shown in Fig. 4 A, treatment
with anti-CD40L mAb, but not the control antibody, sig-
nificantly blunted the clonal expansion of KJ1261CD41
cells in vivo. The dramatic effect that FL treatment has on
the in vitro proliferation of OVA-specific T cells is also
greatly reduced as a result of blocking the CD40–CD40L
pathway in vivo (Fig. 4 B). This is consistent with reports
ascribing a pivotal role to CD40–CD40L interaction in the
onset of T cell–dependent immune responses (30–33).
FL Is Able to Prevent the Establishment of Peripheral Tolerance
Caused by Systemic Injection of a Soluble Antigen. Injection
of soluble antigens into mice is known to induce antigen-
specific T and B cell tolerance rather than immunity (2–6,
9). It has been proposed that this outcome may be due to
antigen presentation to T cells by poorly stimulatory, rest-
ing B cells (11, 12, 14). Since the profound expansion in
DCs caused by FL treatment dramatically enhances anti-
gen-specific T and B cell responsiveness to soluble anti-
gens, we investigated whether FL treatment could prevent
the tolerance induction caused by systemic injection of sol-
uble antigen. BALB/C mice, which had been reconstituted
previously with transgenic T cells, were injected intraperi-
toneally with 1 mg of OVA, in either the presence or ab-
sence of FL treatment (Fig. 5 A). 7 d later, mice were chal-
lenged with OVA in CFA (OVA/CFA) in the footpads.
The OVA-specific T cell response was monitored by flow
cytometry as described above. OVA/CFA elicits an anti-
gen-specific T cell response, and, as shown previously (8),
injection of OVA before challenge with OVA/CFA in-
duces a state of impaired responsiveness, evidenced by a
reduction in the frequency and the absolute numbers of
KJ1261CD41 cells, compared with the OVA/CFA con-
trols (Fig. 5, B and C). In contrast, mice that received OVA
in the presence of FL treatment responded even better than
the mice that had not been pretreated with OVA before
challenge immunization with OVA/CFA. Therefore FL
treatment appears to prevent the nonresponsiveness caused
by soluble antigen.
Thus the in vivo expansion in DCs caused by FL treat-
ment is able to enhance immune responses dramatically
against a soluble antigen via a mechanism involving CD40–
CD40L interaction, and bypass the induction of peripheral
tolerance caused by systemically administered soluble anti-
gen. These results are consistent with the recently de-
scribed ability of FL to augment both antitumor immunity
(34) and rejection of allogeneic transplants (35). They also
support the recent observations of Gong et al. (36) that hy-
bridoma DCs can abrogate T cell tolerance to tumor anti-
gens in transgenic mice. However, our results differ from a
recent report that describes the effect of FL in enhancing
oral tolerance to fed soluble antigens at certain low doses of
antigen (37). The contrasting effects of FL treatment on T
cell tolerance to orally versus systemically administered an-
tigens is reminiscent of the effects that LPS has on tolerance
induced by these different routes of antigen administration.
Although LPS is known to abrogate peripheral tolerance (8,
17), several reports describe its ability to enhance oral toler-
ance (e.g., 38). The reason(s) for the differences between
Figure 4. Effect of in vivo CD40–CD40L blockade on the expansion of antigen-specific T cells in vivo and in vitro. (A) The blockade of CD40–CD40L
interaction in vivo with the M158 antibody (200 mg administered intraperitoneally on days 21, 0, 11, and 12) significantly blunts the clonal expansion of
antigen-specific T cells in FL-treated mice and OVA/CFA-immunized mice. Each dot represents a single mouse and histograms represent the arithmetic
means. (B) Upon restimulation in vitro with varying concentrations of OVA 323–339 peptide, there is a profound impairment of proliferative capacity in
mice that received the M158 antibody. h, OVA 1 FL; e, OVA 1 FL 1 control IgG; s, OVA 1 FL 1 anti-CD40L; n, OVA/CFA 1 control IgG;
quartered square, OVA; r, OVA 1 control IgG. Data pooled from two independent experiments in which three to five mice per group were used.2081 Pulendran et al.
our observations and those of Viney et al. (37) are unclear at
present, but may well reside in the functional differences in
DC subsets, or in differences in the microenvironments be-
tween the gut and peripheral lymphoid organs.
The exact mechanism by which FL treatment enhances
immune responses is unclear. It is useful to consider this
question in the context of the recent observation that the
establishment of T cell anergy by soluble antigens in vivo
may be dependent on the interaction between B7 mole-
cules on APCs and CTLA-4 on T cells (39). This mecha-
nism of T cell tolerance is likely to occur when the APC
expresses very low levels of B7 molecules, resulting in a
preferential interaction with the high affinity CTLA-4 re-
ceptor rather than with CD28. In FL-treated mice, there is
an enormous expansion of CD861 DCs in the T cell zones
and marginal zones of spleens (22). It is possible that this in-
creased surface area and density of CD861CD401class II1
APCs in the T cell zones alters the balance between toler-
ance and immunity and results in soluble antigen being
presented to T cells in an immunogenic way.
In summary, these data provide evidence for DCs play-
ing a pivotal role in maintaining the equilibrium between
immunity and self-tolerance in vivo, and highlight the po-
tential for FL as a vaccine adjuvant.
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